Trump Order Boosts Psychedelic Drug Stocks

President Trump's recent executive order expediting the development of psychedelic drugs has sent shockwaves through the pharmaceutical sector. Companies like Atai and Beckley, along with Compass Pathways, are experiencing significant stock surges. These firms are at the forefront of developing psychedelic treatments for conditions such as depression. The order signals a potential shift in regulatory attitudes towards these novel therapies, opening doors for further research and commercialization. This development could mark a turning point for the burgeoning psychedelic medicine industry.